Ranking Alexa Global: # 18,252,767
Server:nginx...
The main IP address: 89.111.176.180,Your server Russian Federation,Saint Petersburg ISP:CJSC Regional Network Information Center TLD:ru CountryCode:RU
The description :clinical trials in russia - synergy research group....
This report updates in 15-Aug-2018
Created Date: | 2014-09-05 |
Expires Date: | 2017-09-05 |
Geo IP provides you such as latitude, longitude and ISP (Internet Service Provider) etc. informations. Our GeoIP service found where is host synergycro.ru. Currently, hosted in Russian Federation and its service provider is CJSC Regional Network Information Center .
Latitude: | 59.894439697266 |
Longitude: | 30.264169692993 |
Country: | Russian Federation (RU) |
City: | Saint Petersburg |
Region: | Saint Petersburg City |
ISP: | CJSC Regional Network Information Center |
HTTP Header information is a part of HTTP protocol that a user's browser sends to called nginx containing the details of what the browser wants and will accept back from the web server.
Content-Encoding: | gzip |
Transfer-Encoding: | chunked |
Set-Cookie: | a29fa29e0d5ae852c6900d3c106a4ed6=f45d925ef9d7c52039be33c44e9bfcd5; path=/ |
Expires: | Wed, 15 Aug 2018 09:33:58 GMT |
Keep-Alive: | timeout=5 |
Server: | nginx |
Connection: | keep-alive |
Pragma: | no-cache |
Cache-Control: | no-cache, max-age=3600 |
Date: | Wed, 15 Aug 2018 08:34:01 GMT |
P3P: | CP="NOI ADM DEV PSAi COM NAV OUR OTRo STP IND DEM" |
Content-Type: | text/html; charset=windows-1251 |
soa: | ns1.hc.ru. support.hc.ru. 2018052938 3600 1800 604800 3600 |
txt: | "v=spf1 ip4:80.84.121.197 ip4:77.246.225.226 ip4:80.84.123.107 a mx ~all" |
ns: | ns1.hc.ru. ns2.hc.ru. |
ipv4: | IP:89.111.176.180 ASN:41126 OWNER:CENTROHOST-AS, RU Country:RU |
mx: | MX preference = 10, mail exchanger = mx1.synergycro.ru. MX preference = 100, mail exchanger = mx100.synergycro.ru. |
+++july 2018: russian moh approved our new phase ii study in patients with inoperable or metastatic melanoma with braf v600 mutation+++ new cra i hired in almaty+++ june 2018: the first site was initiated in phase iii study in patients with asthma uncontrolled and elevated eosinophil levels+++ the first site was initiated in phase iii study in patients with autoimmune pulmonary alveolar proteinosis+++ the first three patients are randomized into phase iii study to compare solutions used for preservation of the transplanted organs+++ an article of our director of clinical operations evgeny poltanov was published in journal for clinical studies+++may 2018: new cra iii hired in kiev, new cra i and cra ii in moscow+++ a new be study started+++ russian moh approved our new nis study in patients with autoimmune pulmonary alveolar proteinosis+++ the first patient is randomized into phase iii study in patients with multiple sclerosis+++ april 2018: synergy took part in the international exhibition of pharmaceuticals, engineering and biotechnology ipheb russia 11–13 april 2018 in saint-petersburg. during ipheb russia educational programme our speaker evgeny poltanov shared his experience in people management in clinical trials+++ new cra ii hired in yekaterinburg+++ march 2018: new ctas hired in moscow and kiev, new cra i in novosibirsk +++ ukrainian m oh approved our new phase iii study in patients suffering from amyotrophic lateral sclerosis (als)+++ the first patients are randomized into phase iii study in adults with nasal congestion caused by acute upper respiratory tract infection+++first site was initiated in phase i study in healthy volunteers+++first site was initiated in phase iii study to compare solutions used for preservation of the transplanted organs+++february 2018: the first patient is randomized into phase iii study in elderly patients to prevent cognitive disorders after extensive surgical operations+++first site was initiated in phase iii study in adults with nasal congestion caused by acute upper respiratory tract infection+++the last patient was randomized into phase iii study in patients with idiopathic menorrhagia+++ january 2018:a new phase iii study started in canada in patients suffering from amyotrophic lateral sclerosis (als)+++ new ctas hired in moscow and saint-petersburg!+++ december 2017: the last patient was randomized into phase iii study in patients with facial acne vulgaris+++ new chief strategy officer appointed+++clinical database was locked for our be study+++november 2017: the last patient was randomized into phase ii study in patients with her2 negative, er positive metastatic breast cancer+++ october 2017: the first patient is randomized into phase iii study in patients with vasomotor symptoms +++ new be study started +++ september 2017: new phase iii study in patients with facial acne vulgaris started in georgia and ukraine +++ july 2017: new phase iii study in elderly patients with cognitive dysfunction after minor surgery started in russia +++ june 2017: the first patient is randomized in ukraine in a phase iii study in patients with facial acne vulgaris +++ may 2017: a new study in patients with nasal congestion caused by an acute upper respiratory tract infection started +++ the first patient is randomized into phase iii study in patients with facial acne vulgaris +++ 300 patients are randomized in time in phase iii study in patients with overactive bladder +++ april 2017: three new studies started in russia, ukraine and lithuania +++ march 2017: the first patient is randomized into phase 2-3 study in patients with metastatic colorectal cancer +++ the first patient is recruited in a studyefficacy and safety of the biosimilar in comparison to the original in patients with neovascular age-related macular degeneration +++ december 2016: the first patient is screened in ukraine in phase iii study in patients with asthma uncontrolled with high dose of inhaled corticosteroids +++ two new be studies were started in december +++ new phase iii study in patients with facial acne vulgaris is started in ukraine and georgia +++ [ about us ] [ cro services ] [ expertise ] [ analytics ] [ why?.. ] [ contact ] © synergy research group, 2007-2018 all rights reserved | disclaimer | anti-corruption policy | authorized access news & events
http://www.synergycro.ru/analytics.html
http://www.synergycro.ru/why-synergy.html
http://www.synergycro.ru/contact.html
http://www.synergycro.ru/cro-services.html
http://www.synergycro.ru/about-us.html
Whois is a protocol that is access to registering information. You can reach when the website was registered, when it will be expire, what is contact details of the site with the following informations. In a nutshell, it includes these informations;
% By submitting a query to RIPN's Whois Service
% you agree to abide by the following terms of use:
% http://www.ripn.net/about/servpol.html#3.2 (in Russian)
% http://www.ripn.net/about/en/servpol.html#3.2 (in English).
domain: SYNERGYCRO.RU
nserver: ns1.hc.ru.
nserver: ns2.hc.ru.
state: REGISTERED, DELEGATED, VERIFIED
org: OOO "Sinerdzhi Reserch Grupp"
registrar: R01-RU
admin-contact: https://partner.r01.ru/contact_admin.khtml
created: 2014-09-05T08:16:38Z
paid-till: 2017-09-05T09:16:38Z
free-date: 2017-10-06
source: TCI
Last updated on 2017-06-29T07:56:30Z
REFERRER http://www.ripn.net
REGISTRAR RUCENTER-REG-RIPN
SERVERS
SERVER ru.whois-servers.net
ARGS synergycro.ru
PORT 43
TYPE domain
DISCLAIMER
By submitting a query to RIPN's Whois Service
you agree to abide by the following terms of use:
http://www.ripn.net/about/servpol.html#3.2 (in Russian)
http://www.ripn.net/about/en/servpol.html#3.2 (in English).
DOMAIN
NAME synergycro.ru
NSERVER
NS1.HC.RU 89.111.177.252
NS2.HC.RU 79.174.74.74
STATUS REGISTERED, DELEGATED, VERIFIED
CREATED 2014-09-05
EXPIRES 2017-09-05
SOURCE TCI
OWNER
ORGANIZATION OOO "Sinerdzhi Reserch Grupp"
REGISTERED yes
The following list shows you to spelling mistakes possible of the internet users for the website searched .